Weight Loss Injections and Fertility: What You Need to Know Before Starting

What official guidance actually says about GLP-1 medicines and conception

The clearest guidance on this topic comes from the prescribing information published on the UK's electronic medicines compendium and from NHS England's clinical resources on weight-management injections. Both tirzepatide (Mounjaro) and semaglutide (Wegovy) carry an explicit recommendation that women should stop treatment before trying to conceive. The reason is straightforward: there is not yet sufficient evidence from human pregnancies to confirm these medicines are safe during conception or fetal development, and animal studies with tirzepatide showed adverse reproductive effects at exposures relevant to human doses.

The MHRA's public guidance on GLP-1 medicines reinforces that these treatments are not assessed for use in pregnancy and advises stopping well in advance of attempting conception, with the exact washout window determined by the prescriber based on the medicine and the individual. For semaglutide, the half-life is notably long (the medicine takes approximately five weeks to clear substantially) so planning ahead matters more than many people initially expect.

There is a misconception worth addressing gently here: that stopping the injection a week or two before trying is sufficient. Given the pharmacokinetics involved, the appropriate window is longer, and this is a decision to make with a clinician who knows your full medical picture, not a rule of thumb from an online search.

The clinical eligibility assessment at nume always explores family planning intentions for women of childbearing age precisely because timing treatment correctly matters.

The contraception interaction unique to tirzepatide

One finding that surprises people is that tirzepatide specifically affects how well oral contraceptives are absorbed. Because tirzepatide slows gastric emptying, medications taken orally (including the pill) pass through the stomach more slowly, which can reduce their absorption in the early phase of treatment and at each dose increase.

NHS guidance, reflected on the NHS Inform Scotland resource for diabetes and weight-loss medication, advises that women taking oral contraceptives should switch to, or add, a non-oral method (a condom, patch, or implant, for example) for the first four weeks of tirzepatide treatment and for four weeks after each dose step up. This is not the same for semaglutide: the current evidence does not show an equivalent reduction in pill absorption with Wegovy.

This distinction matters for people whose contraceptive reliability is important during treatment. If you are using the pill and considering tirzepatide, discussing your contraceptive plan with the prescriber before starting is part of responsible clinical practice, not an optional extra. You can read more about how weight-loss injections may affect fertility and the contraception picture in more detail.

How obesity affects fertility, and where treatment fits in

The evidence linking excess weight to impaired fertility is substantial. Adipose tissue alters sex hormone levels (it converts androgens to oestrogens in a way that disrupts the normal hormonal cycle) and this can suppress ovulation, lengthen or irregular cycles, and reduce the chance of natural conception. People with polycystic ovary syndrome are particularly affected: PCOS and obesity interact in ways that compound insulin resistance and the hormonal signals that should trigger ovulation.

Weight loss (achieved by any evidence-based method) improves these markers. Clinical research cited in NICE guidance and wider reproductive medicine literature documents improvements in menstrual regularity and ovulation rates following meaningful weight reduction. The SURMOUNT-1 trial of tirzepatide, published in the New England Journal of Medicine, recorded average body-weight reductions of around 20% at the highest dose in people with obesity who did not have diabetes. Reductions of that scale reliably shift metabolic and hormonal parameters, including those relevant to reproductive health.

The practical implication for someone planning a family is that losing weight before conception, then stopping treatment with appropriate lead time, may be the most fertility-positive use of these medicines. The plan needs to be coordinated with a reproductive specialist or GP alongside the weight-management prescriber. If you are exploring what treatment is available and what it involves, our treatment overview is a good starting point, and our clinical team can discuss your individual circumstances during the consultation.

Planning treatment around family planning: who to talk to and when

Anyone using, or considering, weight-loss injections who has questions about fertility should bring those questions into the prescribing consultation from the outset, not after the first pen has been used. A GPhC-registered Independent Prescriber can advise on timing, contraceptive choice, and the appropriate point to stop treatment before conception, and if you want background on what MS means in the context of weight loss injections, that page sets out the details clearly. For people undergoing fertility investigations or treatment (IVF, ovulation induction, or hormonal monitoring) the fertility team needs to know about any GLP-1 medicine in use, including the dose and how long the person has been on it.

For those already on treatment who are now considering pregnancy sooner than expected, the right step is to contact the prescribing service promptly rather than self-managing the stop. You can reach our team via our contact page at any time, seven days a week. There are also separate questions about whether these medicines cause infertility directly, the evidence does not suggest they do, and that page addresses the distinction carefully.

People who cannot use injections, or who are exploring non-injectable options, can find information about oral weight-loss medication as an alternative path. As always, suitability for any treatment is decided through proper clinical assessment, individual circumstances, history, and goals all shape the right answer. The general FAQs cover many of the questions that come up around eligibility and the process.